Welcome to our dedicated page for MIRA PHARMACEUTICALS SEC filings (Ticker: MIRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MIRA PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MIRA PHARMACEUTICALS's regulatory disclosures and financial reporting.
MIRA PHARMACEUTICALS, INC. reported that director Shekhat Denil Nanji received a grant of stock options to buy 50,000 shares of common stock at an exercise price of $0.94 per share on June 12, 2026. The options were granted under the company’s 2022 Omnibus Incentive Plan as compensation, not as an open‑market purchase.
According to the grant terms, 50% of the options vest six months after the grant date and the remaining 50% vest one year after the grant date. The options expire on June 12, 2036 if not exercised. After this award, Nanji holds 50,000 stock options directly.
MIRA PHARMACEUTICALS, INC. filed an initial ownership report (Form 3) for Andriy Mushak, who serves as Chief Financial Officer. The filing does not list any transactions or holdings, functioning primarily as a baseline disclosure of his status as an officer subject to insider reporting rules.
Mira Pharmaceuticals is changing its finance leadership, with Chief Financial Officer Alan Weichselbaum ending his service effective June 6, 2026. The company states his departure is not due to any disagreement over operations, policies, or practices.
On June 2, 2026, the board appointed Andriy Mushak as fractional Chief Financial Officer, effective June 6, 2026. Mushak, a 43-year-old Certified Public Accountant with over 20 years of SEC reporting and audit experience, will provide services through LMAM Consulting Group, LLC under a consulting agreement, for which he will be paid $6,000 per month. The filing notes no relevant family relationships or related-party transactions requiring disclosure.
MIRA Pharmaceuticals entered an Amended and Restated Exclusive License Agreement with MIRALOGX LLC, securing worldwide exclusive rights to its MIRA-55 and SKNY-1 programs. The agreement grants global rights to develop, manufacture, commercialize, sublicense and enforce intellectual property for these assets, consolidating ownership across MIRA’s core pipeline.
The company states the amendment does not materially change previously disclosed core economic terms of the license. MIRA-55 is an oral investigational cannabinoid analog for chronic inflammatory pain, with the DEA confirming it is not classified as a controlled substance. SKNY-1 is an oral investigational candidate targeting obesity and addiction-related disorders with preclinical evidence of dose-dependent weight and lipid effects.
Management highlights that MIRA now controls global development and commercialization rights for Ketamir-2, MIRA-55 and SKNY-1, aiming for Phase 2a advancement of Ketamir-2 and IND filings for MIRA-55 and SKNY-1 under a unified worldwide rights structure.
MIRA Pharmaceuticals, Inc. entered into an amendment to its exclusive Ketamir-2 license with MIRALOGX, expanding its licensed territory from North America to all countries where patent rights exist. The amendment also adds international patent filings across major markets including the United States, Europe, China, Japan, Canada, Australia, India, Israel, Mexico, and South Korea.
The company describes this expanded intellectual property coverage as supporting its global development and commercialization strategy for Ketamir-2, which is advancing toward planned Phase 2a testing in chemotherapy-induced peripheral neuropathy. The amendment does not materially change the core economic terms of the original license, such as royalties and other financial obligations.
MIRA Pharmaceuticals, Inc. reported a first-quarter 2026 net loss of $1,150,152 with no revenue, reflecting its clinical-stage focus on Ketamir-2, MIRA-55, and SKNY-1. Research and development expenses were $524,781 and general and administrative expenses were $578,698, both key drivers of the loss.
Cash was $4,815,031 and total assets were $9,463,736 as of March 31, 2026, with stockholders’ equity of $9,348,975 and minimal liabilities. The company recorded a $91,582 loss from its equity method investment in Telomir Pharmaceuticals. It used $1,201,283 of cash in operating activities in the quarter.
Management expects existing cash to fund operations into at least the first quarter of 2027, but states that current cash and cash equivalents are insufficient to support operations for 12 months from the financial statement issuance date. This, along with ongoing losses and funding needs for future trials, raises substantial doubt about MIRA’s ability to continue as a going concern absent additional financing.
MIRA Pharmaceuticals reported positive unblinded results from a completed Phase 1 trial of Ketamir-2, its selective oral NMDA receptor modulator. In this randomized, double-blind, placebo-controlled study, 57 healthy volunteers across seven cohorts completed treatment with no withdrawals, no serious adverse events and no dose-limiting toxicities. Most side effects were mild, and adverse events were reported more often in the placebo group than in Ketamir-2 recipients.
Pharmacokinetic data showed rapid oral absorption and dose-proportional Cmax, with Ketamir-2 half-life ranging from about 2.5 to 7 hours and its active metabolite nor-Ketamir-2 from about 7 to 9 hours, suggesting potential for once-daily dosing after further evaluation. The company is preparing a Phase 2a protocol under its active IND to test Ketamir-2 in chemotherapy-induced peripheral neuropathy and noted that the DEA determined Ketamir-2 is not a controlled substance.
MIRA Pharmaceuticals filed an 8-K to highlight new preclinical data on SKNY-1, its investigational oral drug candidate for obesity and nicotine addiction. A peer-reviewed manuscript in the International Journal of Molecular Sciences describes SKNY-1’s pharmacology and effects in an MC4R-deficient zebrafish obesity model.
The study reports that oral SKNY-1 produced dose-dependent weight loss over six days, including about a 30% reduction in body weight from baseline in the higher-dose group, with no significant reduction in whole-body density. It also details improvements in cholesterol measures, liver triglycerides, appetite-related gene expression, and compulsive feeding and nicotine-seeking behaviors.
The company emphasizes these findings are from zebrafish and in vitro systems only. SKNY-1 is not FDA approved, and its safety and efficacy in humans are not established.
MIRA PHARMACEUTICALS, INC. reported an equity compensation award to its Chief Executive Officer, Erez Aminov. On March 30, 2026, he was granted 83,500 restricted stock units (RSUs), each representing the right to receive one share of common stock.
The footnotes state that all of these RSUs vested on the grant date, meaning the award became fully earned immediately. Following this grant, Aminov held 83,500 RSUs directly, with an expiration date of March 30, 2036. This is a compensation-related acquisition, not an open-market stock purchase or sale.
MIRA Pharmaceuticals, Inc. reports its annual results as a clinical-stage biotech with no revenue and a substantial accumulated deficit of $39.6 million as of December 31, 2025. The company warns of substantial doubt about its ability to continue as a going concern beyond the third quarter of 2025 without new financing.
MIRA is advancing three oral drug candidates: Ketamir-2 for neuropathic pain, MIRA-55 for inflammatory and CNS-related pain, and SKNY-1 for obesity and nicotine dependence. Ketamir-2 has completed Phase 1 dosing with no serious adverse events reported to date, and a Phase 2a trial in chemotherapy-induced peripheral neuropathy is planned for 2026, subject to regulatory review and resources.
The DEA has concluded that Ketamir-2, MIRA-55, and SKNY-1 are not currently controlled substances, which may ease development. However, operations rely heavily on external licensing (notably from MIRALOGX), at-the-market equity sales, and a very small team of two part-time employees and consultants, underscoring execution and financing risk.